Dab and Concentrate Withdrawal: Why It Hits Harder
Withdrawal & Recovery
90% THC
Cannabis concentrates deliver 60 to 90% THC compared to 15 to 25% for flower, pushing CB1 receptors further down and producing withdrawal symptoms that are measurably more severe and longer-lasting.
Biological Psychiatry, 2016
Biological Psychiatry, 2016
View as imageConcentrates have changed what it means to use cannabis. A single dab of wax or shatter can deliver more THC in one inhale than an entire joint of flower. That shift in potency is not just a matter of getting higher. It changes how your brain adapts to THC, how deep that adaptation goes, and what happens when you try to stop. If you have been using dabs, wax, shatter, or live resin (and its solventless counterpart, live rosin) regularly and you are thinking about quitting, or if you have already tried and were caught off guard by how rough it was, this is the information you need.
Key Takeaways
- Dabs, wax, shatter, and live resin deliver 60 to 90% THC — compared to 15 to 25% for flower — so your brain adapts much more deeply to concentrates
- That heavier THC load pushes your CB1 receptors further down, which is why withdrawal hits harder when you stop using concentrates
- You get the same withdrawal symptoms as flower users — insomnia, irritability, anxiety, appetite loss — but they are often more severe and can drag on longer
- Daily use of high-potency cannabis carries about five times the risk of a first psychotic episode compared to never using
- Stepping down to flower before quitting entirely is one strategy, but it does not work for everyone and is not the only option
- Your risk of cannabinoid hyperemesis syndrome (CHS) goes up with concentrates because higher THC loads per session compress the cumulative exposure that triggers the condition
What Makes Concentrates Different
The core difference is THC concentration. Most cannabis flower sold today contains somewhere between 15 and 25% THC. Concentrates, depending on the type, typically range from 60 to 90% THC. Some distillates push above 90%. Products like moon rocks, which combine flower, oil, and kief, push potency even further. If you are unsure how resin, rosin, and live rosin differ from each other, the resin vs rosin vs live rosin guide explains the extraction methods and what they mean for potency.
This is not a small difference. A 2016 analysis by ElSohly and colleagues, published in Biological Psychiatry, documented[1] that average THC content in cannabis roughly tripled between 1995 and 2014, rising from approximately 4% to approximately 12%. That analysis focused on flower. Concentrates represent yet another leap beyond those already elevated numbers.
The second factor is speed of delivery. Dabbing involves vaporizing concentrate on a heated surface and inhaling the result. This delivers a massive dose of THC to your lungs and then your bloodstream in seconds. The faster a substance reaches your brain, the more intensely it activates your reward system. This is the same principle that makes smoking a drug more addictive than swallowing it, and it applies within cannabis consumption methods as well. For a broader comparison of how different methods affect your body, the harm reduction guide to vaping vs smoking vs edibles breaks down each delivery route.
The third factor is what is missing. ElSohly's analysis also found that as THC content climbed, CBD content (cannabidiol, a compound that partially counteracts some of THC's effects) decreased. Most concentrates are produced to maximize THC and contain minimal CBD. You are getting a more potent, less balanced neurochemical signal than flower delivers.
Why Withdrawal Hits Harder
Withdrawal symptoms from cannabis are caused by CB1 receptor downregulation. When you use THC regularly, your brain reduces both the number and sensitivity of CB1 receptors to compensate for the constant stimulation. When you stop using, those receptors are depleted, and your endocannabinoid system cannot function normally until they recover.
A 2012 brain imaging study by Hirvonen and colleagues, published in Molecular Psychiatry, confirmed this directly.[2] Using PET scans, the researchers showed that chronic cannabis users had significantly reduced CB1 receptor availability throughout the brain. The good news from that study was that receptors began normalizing after about four weeks of abstinence. The key detail is that the degree of downregulation is related to the amount of THC your brain has been exposed to.
This is where concentrates matter. If you are consuming 60 to 90% THC multiple times per day, your CB1 receptors are being pushed further down than someone using 20% THC flower. More downregulation means a bigger gap between where your receptors are and where they need to be when you stop. That gap is withdrawal.
The marijuana withdrawal symptoms are the same regardless of consumption method: insomnia, irritability, anxiety, decreased appetite, restlessness, depressed mood, and sometimes physical symptoms like sweating and headaches. Research by Budney and colleagues, published in 2003 in the Journal of Abnormal Psychology, established[3] this symptom profile and timeline. Symptoms typically peak within the first week and resolve over two to four weeks.
But severity varies. People who use concentrates frequently report that their withdrawal is on the more intense end of that spectrum. The underlying biology supports this. Heavier THC exposure means deeper receptor adaptation means more intense rebound when that exposure stops.
The Tolerance Escalation Problem
One pattern that shows up repeatedly with concentrate users is a specific trajectory. It starts with flower. Over time, tolerance builds and flower stops producing the same effect. You need more to get the same result. At some point, someone introduces concentrates as a solution to that tolerance problem.
Concentrates work, at first. The massive THC dose breaks through the tolerance you built on flower. But your brain adapts to this new level of input, and now your tolerance baseline has shifted dramatically upward. Flower barely registers anymore. You need concentrates just to feel normal, and you need increasing amounts of concentrates to feel high.
This is not a moral failure. It is basic neuropharmacology. Your brain is doing exactly what it is designed to do: adjusting to repeated stimulation. The problem is that concentrates allow you to push that adjustment further and faster than flower ever could. Understanding whether weed is addictive means understanding this tolerance-dependence cycle, and concentrates accelerate it significantly.
About 47% of people who use cannabis regularly and then stop will experience clinically significant withdrawal symptoms, according to a 2020 meta-analysis by Bahji and colleagues published in JAMA Network Open.[4] That number likely skews higher among concentrate users, though specific research on concentrate withdrawal prevalence is still limited.
The CHS Connection
Cannabinoid hyperemesis syndrome (CHS) is a condition where chronic heavy cannabis use triggers severe, cyclical vomiting. If you are using concentrates heavily, your risk of developing CHS is elevated.
A 2012 review by Simonetto and colleagues, published in Mayo Clinic Proceedings, analyzed[5] 98 patients with CHS. They found that 68% had been using cannabis for more than two years before CHS symptoms appeared, and 95% were using more than weekly. The hallmark of CHS is that hot showers or baths provide temporary relief when nothing else does.
The connection to concentrates is straightforward. CHS appears to be triggered by cumulative THC exposure over time. The more THC you consume per session and per day, the faster you accumulate that exposure. Someone using concentrates daily is loading their system with several times more THC than a daily flower smoker. There is no research yet establishing exact CHS risk by consumption method, but the pharmacology strongly suggests that higher-potency products compress the timeline.
If you are experiencing cyclical nausea or vomiting and you use concentrates regularly, read the full breakdown on cannabinoid hyperemesis syndrome. CHS is widely underdiagnosed and frequently mistaken for other conditions.
Psychosis Risk and High-Potency Cannabis
THC Potency Pyramid: Why Concentrates Hit Harder
Maximum CB1 flooding; severe downregulation; hardest withdrawal
Convenience + potency = rapid tolerance escalation
5× psychosis risk with daily high-potency use
Modern strains — still 3–6× stronger than 1990s cannabis
The baseline most older research was conducted on
Key finding: Daily high-potency cannabis use (above 10% THC) is associated with 5× higher psychosis risk compared to never-users.
A 2019 study by Di Forti and colleagues, published in The Lancet Psychiatry, found[6] that daily cannabis use was associated with approximately three times the risk of a first psychotic episode. Daily use of high-potency cannabis (defined as THC content above 10%) pushed that risk to approximately five times higher than people who had never used cannabis.
Concentrates are, by definition, high-potency. If you are dabbing daily, you are in the category this research is describing. This does not mean you will develop psychosis. The baseline risk is relatively low, and even a fivefold increase still means the majority of daily users will not experience a psychotic episode. But the risk is real, it is dose-dependent, and it is worth knowing about.
The Di Forti study also found that 29.5% of patients presenting with a first episode of psychosis were daily cannabis users, compared to just 6.8% of matched controls. This was an observational study, not proof of direct causation, but the pattern is consistent and has been replicated across multiple research groups.
If you have a family history of schizophrenia, bipolar disorder, or other psychotic disorders, this risk calculation changes significantly. Genetic vulnerability combined with daily high-potency concentrate use is a combination the research consistently flags as concerning.
Quitting Concentrates: Cold Turkey vs. Stepping Down
There are two basic approaches, and neither is universally better than the other.
Cold Turkey
Stop all cannabis use at once. This produces the most intense withdrawal, but it also starts the recovery clock immediately. Hirvonen's 2012 research showed[2] that CB1 receptors begin recovering and largely normalize within about 28 days of complete abstinence. Every day without THC is a day your receptors are rebuilding.
The first week is typically the hardest. That is when symptoms peak, as research by Budney (2003) documented.[3] Insomnia, irritability, and anxiety tend to be at their worst during days three through seven. For concentrate users, these symptoms may be more intense than what flower-only users experience, but the timeline follows a similar pattern.
For a detailed walkthrough of what to expect, see the cannabis withdrawal complete guide.
Stepping Down to Flower First
Some people find success by transitioning from concentrates to flower for a period before quitting entirely. The logic is that you are reducing your THC intake significantly (from 60 to 90% down to 15 to 25%) without going to zero. This gives your receptors a partial recovery period before you make the full jump.
This approach has trade-offs. On the positive side, it can make the eventual full withdrawal less severe. On the negative side, it extends the overall timeline, requires discipline to not drift back to concentrates, and keeps you in a pattern of use that you are trying to leave. Some people find that having any cannabis available makes it harder to quit, and the step-down becomes a way to delay rather than progress.
There is no clinical research specifically comparing cold turkey versus tapering for concentrate users. The choice depends on your personal patterns, what has worked or failed for you before, and how much structure you have around the process.
Practical Strategies
Regardless of which approach you choose, several things help.
Remove the hardware. Dab rigs, torches, e-nails, and concentrate containers should be out of your living space. The friction between wanting to use and actually being able to use matters. The easier it is to dab, the harder it is to resist during peak withdrawal.
Expect sleep disruption. Insomnia is one of the most common and persistent withdrawal symptoms, and concentrate users often report it being particularly bad. It typically improves after the first two weeks. If you are using weed vape pens alongside dabs, removing those too is important, as keeping one THC source while quitting another undermines the process.
Tell someone. Withdrawal is easier to manage when you are not managing it alone. This does not have to be a therapist (though that helps). A friend, partner, or family member who knows what you are going through can make the rough days more manageable.
Track your progress. The early days feel endless, but knowing that receptors measurably recover within about four weeks gives you a concrete timeline to hold onto.
When to Seek Professional Help
If withdrawal symptoms are severe enough to interfere with your daily functioning, or if you are experiencing thoughts of self-harm, intense panic attacks, or symptoms that feel beyond what you can manage on your own, professional support is available.
SAMHSA's National Helpline is available at 1-800-662-4357. It is free, confidential, and available 24 hours a day, 7 days a week. You can also text "HELLO" to 741741 to reach the Crisis Text Line.
If you are experiencing severe cyclical vomiting and suspect CHS, seek medical attention. CHS-related dehydration can become a medical emergency.
The Bottom Line
Concentrates like dabs, wax, and shatter deliver 60 to 90% THC compared to 15 to 25% for flower, causing significantly deeper CB1 receptor downregulation. Brain imaging confirms that chronic users have reduced CB1 receptor availability, with recovery taking approximately 28 days of abstinence. Deeper receptor adaptation from concentrates means more intense withdrawal symptoms (insomnia, irritability, anxiety, appetite loss) that can last longer. A 2020 meta-analysis found 47% of regular cannabis users experience clinically significant withdrawal, and this number likely skews higher for concentrate users. Daily high-potency cannabis use carries approximately five times the risk of a first psychotic episode. Cannabinoid hyperemesis syndrome risk is also elevated. Quitting options include cold turkey or stepping down to flower first, with no clinical research definitively favoring either approach for concentrate users.
Frequently Asked Questions
Sources & References
- 1RTHC-01144·ElSohly, Mahmoud A. et al. (2016). “U.S. Cannabis Potency Tripled Over Two Decades While CBD Nearly Vanished.” Biological Psychiatry.Study breakdown →PubMed →↩
- 2RTHC-00573·Hirvonen, Jussi et al. (2012). “Daily Cannabis Use Was Linked to Fewer CB1 Receptors. A Month Without Brought Them Back..” Molecular Psychiatry.Study breakdown →PubMed →↩
- 3RTHC-00134·Budney, Alan J. et al. (2003). “When Heavy Users Quit Cannabis, Symptoms Show Up Fast and Ease Within Two Weeks.” Journal of Abnormal Psychology.Study breakdown →PubMed →↩
- 4RTHC-02407·Bahji, Anees et al. (2020). “About Half of Heavy Cannabis Users Experience Withdrawal. This Meta-Analysis Measured It..” JAMA Network Open.Study breakdown →PubMed →↩
- 5RTHC-00619·Simonetto, Douglas A. et al. (2012). “The 98-Patient Case Series That Shaped Cannabinoid Hyperemesis.” Mayo Clinic Proceedings.Study breakdown →PubMed →↩
- 6RTHC-02010·Di Forti, Marta et al. (2019). “Daily High-Potency Cannabis Use and Psychosis Risk: The Largest European Study Drew a Direct Line.” The Lancet Psychiatry.Study breakdown →PubMed →↩
Research Behind This Article
Showing the 8 most relevant studies from our research database.
Adverse clinical effects associated with the use of synthetic cannabinoids: A systematic review.
Prete, Mariana M · 2025
From 944 studies screened, 49 met inclusion criteria (2010-2022).
Novel psychoactive substances and psychosis: A comprehensive systematic review of epidemiology, clinical features, neurobiology, and treatment.
Ricci, Valerio · 2025
Among 85 studies, synthetic cannabinoids showed consistently higher psychosis risk than traditional cannabis (OR 4.4-5.2 for synthetic cannabinoids vs cannabis).
High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review.
Rittiphairoj, Thanitsara · 2025
In non-therapeutic studies, high-concentration THC showed unfavorable associations with psychosis/schizophrenia (70% of studies) and cannabis use disorder (75%).
A Comprehensive Review of Cannabis Potency in the United States in the Last Decade.
ElSohly, Mahmoud A · 2021
This third installment from the University of Mississippi's Potency Monitoring Program extended the dataset through 2019, adding 14,234 samples to the two previous reports (RTHC-00039 covering 1995-2014 and RTHC-00049 covering 2008-2017). THC continued its upward trajectory, reaching 14.88% in 2018 before a slight dip to 13.88% in 2019.
Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.
Castaneto, Marisol S · 2014
This comprehensive review documented the rapid proliferation of synthetic cannabinoids (SC) as designer drugs since the early 2000s.
A randomised controlled trial of vaporised Δ9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects.
Solowij, Nadia · 2019
CBD alone (400 mg) showed some intoxicating properties vs.
Free and Glucuronide Whole Blood Cannabinoids' Pharmacokinetics after Controlled Smoked, Vaporized, and Oral Cannabis Administration in Frequent and Occasional Cannabis Users: Identification of Recent Cannabis Intake.
Newmeyer, Matthew N · 2016
Researchers gave the same dose of cannabis to both frequent and occasional users through three routes: smoking, vaporizing, and eating.
Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state.
Smart, Rosanna · 2017
Analyzing Washington State's cannabis traceability data from July 2014 to September 2016 (over 44 million purchases), the study revealed several market trends. Traditional cannabis flower still dominated at 66.6% of spending, but extracts for inhalation (concentrates) grew by 145.8% in market share, reaching 21.2% of sales.